These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18381591)

  • 1. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
    Kinyamu HK; Collins JB; Grissom SF; Hebbar PB; Archer TK
    Mol Carcinog; 2008 Nov; 47(11):845-85. PubMed ID: 18381591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.
    Kinyamu HK; Bennett BD; Bushel PR; Archer TK
    J Biol Chem; 2020 Jan; 295(5):1271-1287. PubMed ID: 31806706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression.
    Kinyamu HK; Archer TK
    Mol Cell Biol; 2003 Aug; 23(16):5867-81. PubMed ID: 12897156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.
    Prenzel T; Begus-Nahrmann Y; Kramer F; Hennion M; Hsu C; Gorsler T; Hintermair C; Eick D; Kremmer E; Simons M; Beissbarth T; Johnsen SA
    Cancer Res; 2011 Sep; 71(17):5739-53. PubMed ID: 21862633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
    Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
    Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome activity modulates chromatin modifications and RNA polymerase II phosphorylation to enhance glucocorticoid receptor-mediated transcription.
    Kinyamu HK; Archer TK
    Mol Cell Biol; 2007 Jul; 27(13):4891-904. PubMed ID: 17438138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking.
    Deroo BJ; Rentsch C; Sampath S; Young J; DeFranco DB; Archer TK
    Mol Cell Biol; 2002 Jun; 22(12):4113-23. PubMed ID: 12024025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
    Aka JA; Calvo EL; Lin SX
    Mol Cell Endocrinol; 2017 Jan; 439():175-186. PubMed ID: 27544780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.
    Ogara MF; Rodríguez-Seguí SA; Marini M; Nacht AS; Stortz M; Levi V; Presman DM; Vicent GP; Pecci A
    Nucleic Acids Res; 2019 Nov; 47(20):10645-10661. PubMed ID: 31598691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
    West DC; Pan D; Tonsing-Carter EY; Hernandez KM; Pierce CF; Styke SC; Bowie KR; Garcia TI; Kocherginsky M; Conzen SD
    Mol Cancer Res; 2016 Aug; 14(8):707-19. PubMed ID: 27141101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
    West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
    Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
    [No Abstract]   [Full Text] [Related]  

  • 13. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
    Fan M; Bigsby RM; Nephew KP
    Mol Endocrinol; 2003 Mar; 17(3):356-65. PubMed ID: 12554766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional up-regulation of PHLDA1 by 17beta-estradiol in MCF-7 breast cancer cells.
    Marchiori AC; Casolari DA; Nagai MA
    Braz J Med Biol Res; 2008 Jul; 41(7):579-82. PubMed ID: 18641796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters.
    Kininis M; Chen BS; Diehl AG; Isaacs GD; Zhang T; Siepel AC; Clark AG; Kraus WL
    Mol Cell Biol; 2007 Jul; 27(14):5090-104. PubMed ID: 17515612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative effects of the ubiquitin-proteasome pathway on glucocorticoid receptor down-regulation and transactivation are mediated by CHIP, an E3 ligase.
    Wang X; DeFranco DB
    Mol Endocrinol; 2005 Jun; 19(6):1474-82. PubMed ID: 15761032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells.
    Zhu Q; Huang Y; Marton LJ; Woster PM; Davidson NE; Casero RA
    Amino Acids; 2012 Feb; 42(2-3):887-98. PubMed ID: 21805138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
    Wierer M; Verde G; Pisano P; Molina H; Font-Mateu J; Di Croce L; Beato M
    Cell Rep; 2013 Jun; 3(6):2021-32. PubMed ID: 23770244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genes.
    Vicent GP; Nacht AS; Zaurin R; Font-Mateu J; Soronellas D; Le Dily F; Reyes D; Beato M
    Genes Dev; 2013 May; 27(10):1179-97. PubMed ID: 23699411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.